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Abstract
Development of a Novel Drug 
Carrier Using Cyclodextrins 
Containing Maleic Anhydride 
Moieties 
  뜸 (Euddeum Park)
Department of Chemistry
College of Natural Sciences
Seoul National University
  I developed a new pH-sensitive drug delivery carrier based on 
b-cyclodextrin (b-CD) and 1-methyl-2-(20-carboxyethyl) maleic 
anhydrides (MCM). The primary hydroxyl groups of b-CD were 
successfully attached to MCM residues to produce a medusa-like 
b-CD–MCM. The MCM residue was conjugated with cephradine 
(CP) with high efficiency (>90%). More importantly, b-CD–MCM–CP 
responded to the small pH drop from 7.4 to 5.5 and released 
greater than 80% of the drugs within 0.5 h at pH 5.5. In addition, 
the inclusion complex between b-CD–MCM–CP and the ada-
4
mantane derivative was formed by simple mixing to show the 
possibility of introducing multi-functionality. Based on these re-
sults, b-CD–MCM can target weakly acidic tissues or organelles, 
such as tumours, inflammatory tissues, abscesses or endosomes, 
and be easily modified with various functional moieties, such as 
ligands for cell binding or penetration, enabling more efficient 
and specific drug delivery.
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1. Introduction
  For efficient and safe delivery of drugs to specific targets, 
smart drug delivery techniques have evolved along with the de-
velopment of various signal-responsive materials [1–3].
Abrupt changes in the physicochemical properties of smart mate-
rials in response to physical signals such as temperature [4] and 
light [5] as well as chemical signals such as pH [6], glutathione 
[7], and enzymes [8] can induce encapsulation and release of 
drugs in specific conditions. Among these, pH has been fre-
quently selected as the controlling trigger because the pH value 
can represent a certain physiological condition in many target 
sites in the body. The pH variation through the gastrointestinal 
tract has been used for the site-specific drug delivery to strongly 
acidic stomach or weakly alkaline small intestine [9]. Enhanced 
glycolysis in cancer tissues lowers the pH to 5–6, and similar pH 
lowering is also observed in inflammatory tissues [10] and ab-
scesses [11,12]. The weakly acidic pH value is recognised as an 
inducing signal for the release of anti-cancer [13] or anti-in-
flammatory drugs [14]. Moreover, the early endosomal pH value 
of 5–6 is frequently used as the signal for the endosomal escape 
of macromolecular drugs such as pDNA [15], siRNA [16] or pro-
teins [17], which have difficulty penetrating the cell membrane 
and should be delivered into the cell interior via an endocytic 
pathway [18]. However, smart materials with rapid degradability 
responding to small pH variations are still under active inves-
tigation for a more practical drug delivery system because the 
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pH variation in the human body is not extreme, with a few 
exceptions. As a chemical moiety for pH-responsive smart mate-
rials, maleic acid amide derivatives are attractive owing to their 
rapid degradability at an appropriate pH. Unlike other amides, 
which can only be degraded at extreme pH conditions, maleic 
acid amide derivatives can be degraded within a biologically tol-
erable pH range [19]. The responsive pH range and the degrada-
tion rate can be finely tuned by a change of alkyl substituents 
on the cis-double bonds [20]. Moreover, the maleic acid amide 
derivatives can be synthesised via the onestep ring-opening re-
action between amines and corresponding maleic acid anhydride 
derivatives under weakly alkaline conditions. The easy synthesis 
of maleic acid amide derivatives under mild conditions is a 
strong advantage over other pH-sensitive linkages, which require 
quite complicated synthetic steps in conjugation of drugs or 
cross-linking of carrier backbones [21]. In this study, we wanted 
to synthesise a drug carrier based on 1-methyl-2-(20-carbox-
yethyl) maleic anhydride (MCM) or carboxylate dimethyl maleic 
anhydride (CDM), a maleic acid anhydride derivative with two al-
kyl substituents. Because the acid amide correspondent from 
MCM is stable at normal physiological pH 7.4 but rapidly degrad-
able at pH 5.5 [22], an MCM derivative might be one of the best 
candidates for the conjugation with drugs targeting weakly acidic 
environments. We designed a drug carrier with several MCM res-
idues on the surface for the easiest conjugation with aminebased 
drugs or cross-linkers. As the backbone of the drug carrier, we 
selected b-cyclodextrin (b-CD), a cyclic oligosaccharide with sev-
en glucose molecules. b-Cyclodextrin (b-CD) has been widely 
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used as a part of drug delivery carrier due to its high bio-
compatibility [23]. Many functional groups can be readily in-
troduced into the b-CD backbone because it has 7 primary and 
14 secondary hydroxyl groups. A medusa-like structure can be 
synthesised by reaction with the seven primary hydroxyl groups 
[24]. The regioselective functionalization of b-CD enables to ach-
ieve homogeneous chemical properties of the conjugated func-
tional moieties. Furthermore, the toroidal interior of b-CD can be 
used for the introduction of additional functionality such as a 
targeting ligand [25] or cellpenetrating moiety [26] by host–guest 
inclusion because the nterior can strongly interact with small hy-
drophobic molecules such as adamantane via non-covalent inter-
actions [27]. Polymers or nanoparticles with adamantane moieties 
can be easily modified with b-CD derivatives by the host–guest 
interaction [28]. We expected that the medusa-like b-CD could be 
conjugated with drug molecules via pH-sensitive MCM linkers by 
simple mixing in mildly alkaline conditions and that other func-
tional moieties with adamantane residues could also be non-co-
valently introduced into the pore of the b-CD. Otherwise, the 
surface of other drug carriers such as polymers or nanoparticles 
can be non-covalently modified with the pH-sensitive medusa-like 
b-CD derivative. The resulting carrier could rapidly release the 
conjugated drugs in weakly acidic conditions. The general con-
ceptual scheme is illustrated in Figure 1. By using cephradine 
(CP), a cephalosporin antibiotic, as a drug to be targeted to 
weakly acidic inflammatory tissues, we wanted to prove our con-
cept in vitro. The medusa-like b-CD derivatives has strong po-
tential for multi-functional drug delivery systems for targeting 
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tumours, inflammatory tissues or abscesses as well as for the 
rapid response at the pH of early endosomes in intracellular 
drug delivery.
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2. Materials and methods
2.1. Materials
  CP was obtained from Han Wha Pharm. Co., Ltd. (Seoul, South 
Korea). b-CD, 6-aminohexanoic acid, di-tert-butyl dicarbonate 
((Boc)2O), n-butylamine (BA), triethylamine (TEA), diisopropyle-
thylamine (DIPEA), diisopropylcarbodiimide (DIC), 4-dimethylami-
nopyridine (DMAP), p-toluenesulphonic acid (PTSA), trifluoroacetic 
acid (TFA), sodium hydride (NaH) (60% in mineral oil), 
N,N,N0,N0-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexa-
fluorophosphate (HBTU), fluorescein isothiocyanate (FITC) isomer 
I and dimethylsulphoxide (DMSO) were purchased from 
Sigma-Aldrich(St Louis, MO). Triethyl-2-phosphonopropionate,di-
methyl-2-oxoglutarate and 1-adamantaneamine hydrochloride 
were purchased from TCI (Tokyo, Japan). Ammonium chloride 
(NH4Cl), magnesium sulphate (MgSO4), potassium hydroxide 
(KOH), sodium chloride (NaCl), sodium hydroxide (NaOH), sodium 
bicarbonate (NaHCO3), tetrahydrofuran (THF), dimethylformamide 
(DMF), hexane, ethyl acetate (EA), methanol (MeOH), ethanol, di-
chloromethane (DCM), hydrochloric acid (HCl), acetonitrile (ACN) 
and pyridine were purchased from Daejung (Seoul, South Korea). 
Anhydrous TEA, THF and DMF were obtained by distillation of 
the reagent-grade materials. Other reagents were used without 
further purification.
2.2. Synthesis
  Synthesis of compound 1. 
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Following the method described in a previous report [29], compou
nd 1 was prepared. Briefly, NaH (0.37 g, 9.2 mmol) was added slo
wly into a solution of triethyl-2-phosphonopropionate (1.64 g, 6.8
9 mmol) in anhydrous THF (30 mL) at 0 ˚C under a nitrogen atm
osphere. Dimethyl-2-oxoglutarate (1.00 g, 5.74 mmol) was added t
o the solution after the evolution of hydrogen gas had stopped. T
he reaction mixture was further stirred while maintaining the tem
perature at 0 ˚C. After the reaction completion was confirmed by 
TLC, a saturated aqueous solution of NH4Cl was added dropwise. 
Following the removal of THF by rotary evaporation, the resultin
g solid and water mixture was extracted with EA several times. T
he organic phase was combined, washed with deionised water (DI
W) and brine, dried over MgSO4 and concentrated by rotary evap
oration. The residue was purified by silica gel chromatography el
uted with EA/hexane to yield compound 1 as a colourless oil. Yie
ld: 91%, 1H NMR (300 MHz, CDCl3): d 1.25–1.30 (3H, t, CH3CH2O), 
1.98 (3H, s, CH3C), 2.46–2.49 (2H, m, CCH2CH2), 2.62–2.65 (2H, m, 
CH2CH2CO), 3.66 (3H, s, CO2CH3), 3.73 (3H, s, CH3O2CC) and 4.16–
4.22 (2H, q, CH3CH2O).
Synthesis of compound 2. 
Following the method described in a previous report [29], compou
nd 2 was prepared. Briefly, compound 1 in a 2M KOH solution in 
ethanol was allowed to reflux for 1 h. DIW was added, and the h
ot reaction mixture was cooled to ambient temperature. After re
moval of ethanol by evaporation, the aqueous phase was washed 
with DCM several times and acidified to pH 2 using concentrated 
HCl. The aqueous phase was then extracted with EA several time
s. The organic phase was dried over MgSO4 and concentrated un
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der reduced pressure to produce MCM (2) as a white solid.
Yield: 74%, 1H NMR (300 MHz, CDCl3): d 2.12 (3H, s, CCH3) and 2.
77 (4H, s, CCH2CH2CO).
Synthesis of compound 3. 
To a solution of compound 2 (2.00 g, 1.09 mmol), b-CD (0.10 g, 
0.092 mmol), DMAP (0.46 g, 0.37 mmol) and PTSA (0.70 g, 0.37 m
mol) in DMF (10 mL) was added DIC (0.33 g, 2.6 mmol). The reac
tion mixture was stirred overnight at ambient temperature. The c
rude product was purified by dialysis with regenerated cellulose 
membrane (MWCO 1000, SPECTRUM) in phosphate buffer (pH 9.0), 
HCl solution (pH 3.0) and DIW, respectively. Lyophilisation was pe
rformed next. An off-white power, b-CD–MCM (3) was obtained. Y
ield: 85%, 1H NMR (300 MHz, 1.1 wt% NaOD in D2O): d 1.65 (3H, 
s, CCH3), 1.98–2.10 (2H, m, CCH2CH2), 2.21–2.33 (2H, m, CH2CH2C
O), 3.26–3.36 (2H, m, 20, 40-CH-b-CD), 3.67–3.80 (4H, m, 30, 50-
CH, 60-CH2-b-CD), 4.94 (1H, s, 10-CH-b-CD) (Figure 3a); matrix-
assisted laser desorption ionization-time of flight (MALDI-TOF) (m
/z): 1490, 1656, 1882, 1988, 2155 and 2321 [M+Na]+ (Figure 3b).
Synthesis of compound 4. 
A solution of 3 (0.050 g, 0.024 mmol) in ACN (5 mL) was added w
ith excess TEA at ambient temperature and stirred until becomin
g a completely clear solution. BA (0.24 mL, 0.242 mmol) was adde
d dropwise into the reaction mixture. After overnight stirring, the 
reaction mixture was evaporated to remove the solvents. A 1M N
aOH solution (12 equiv.) was added carefully to the aqueous solut
ion of compound 4 to exchange excess n-butylammonium cations 
with sodium cations. The aqueous crude was evaporated and drie
d in vacuum, and then a light brown powder, b-CD–MCM–BA (4), 
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was obtained. Yield: 490%, 1H NMR (300 MHz, 1.1 wt% NaOD in  
D2O): d 0.89–0.94 (3H, t, CH3CH2), 1.32–1.39 (2H, m, CH3CH2CH2),
1.46–1.54 (2H, m, CH2CH2CH2), 1.87 (3H, s, CCH3), 2.22– 2.31 (2H, 
m, CH2CH3CO), 2.49–2.56 (2H, m, CCH2CH2), 3.18–3.23 (2H, m, CH2
CH2NH), 3.54–3.63 (2H, m, 20, 40-CH-b-CD), 3.65–3.92 (4H, m, 30, 
50-CH, 60-CH2-b-CD), 5.05 (1H, s, 1H, s, 10-CH-b-CD).
Synthesis of compound 5. 
b-CD–MCM–CP (5) was synthesised employing the same preparati
on method as used for compound 4, but using CP solution (6 eq
uiv.) in ACN instead of BA. After purification, yellow solid was ob
tained. Yield:490%, 1H NMR (300 MHz, 1.1 wt% NaOD in D2O): d1.
83 (3H, s, CH3-cephalosporin), 1.86 (3H, s, CCH3), 2.18–2.24 (2H, 
m, CCH2H2), 2.45–2.48 (2H, m, CH2CH2CO), 2.62–2.71 (4H, m, 30, 6
0-CH2-cyclohexadiene), 2.99–3.08 (1H, m, SCH2C-cephalosporin), 
3.12–3.18 (1H, m, SCH2Ccephalosporin), 3.39–3.49 (2H, m, 20, 40-
CH-b-CD), 3.77–3.83 (4H, m, 30, 50-CH, 60-CH2-b-CD), 4.73 (1H, 
s, 10-CCHcyclohexadiene), 4.87 (1H, s, NCHS), 4.90 (1H, s, 10-CH
b-CD), 5.71–5.73 (3H, m, NHCHCO, 40, 50-CH-cyclohexadiene), 5.8
7 (1H, s, 20-CH-cyclohexadiene).
Synthesis of compound 6. 
6-Aminohexanoic acid (1.00 g, 7.26 mmol) was dissolved in the c
o-solvent of THF:aqueous saturated NaHCO3 solution (1:1) and a 
solution of ditert-butyl dicarbonate (2.00 g, 9.15 mmol) in THF w
as added dropwise into the solution at ambient temperature. Afte
r the reaction completion was confirmed by TLC, following the re
moval of THF by rotary evaporation and the resulting solution w
as acidified down to pH 1–2. The mixture was extracted with DC
M several times. The organic phase was combined, washed with d
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eionised brine, dried over MgSO4 and concentrated by rotary eva
poration. The pure compound, N-Boc-aminohexanoic acid (6) was 
obtained as an opaque crystal. Yield: 81%, 1H NMR (300 MHz, 1.1 
wt% NaOD in D2O): d 1.10–1.28 (2H, m, CH2CH2CH2), 1.32–1.56 (13
H, m, CH2CH2CH2CH2CH2, t-Boc), 2.10–2.15 (2H, t, CH2CH2CO2H) an
d 2.99–3.03 (2H, t, NHCH2CH2).
Synthesis of compound 7. 
Following the method described in a previous report [30], compou
nd 7 was prepared. Briefly, a solution of compound 6 (0.10 g, 0.4
3 mmol) and 1-adamantaneamine hydrochloride (0.080 g, 0.43 m
mol) in dry THF (9 mL) was treated with DIPEA (0.12 mL, 0.86 m
mol) and HBTU (0.16 g, 0.43 mmol). After being stirred for 16 h 
at room temperature, the reaction mixture was heated at 60 C fo
r 90 min. Then, DCM and brine were added, and the organic pha
se was washed twice with 1M aqueous HCl (10 mL), twice with 5% 
aqueous NaHCO3 (10 mL) and twice with brine (10 mL), and then 
dried over Na2SO4. The residue was purified by silica gel chromat
ography eluted with EA/hexane to yield compound 7 as a white s
olid. Yield: 54%, 1H NMR (300 MHz, CDCl3): d 1.27–1.35 (2H, m, C
H2CH2CH2), 1.42–1.49 (11H, s, m, t-Boc, CH2CH2CO), 1.55–1.59 (2H, 
m, NHCH2CH2), 1.61–1.65 (6H, br, CCH2CH-ADM), 1.89–1.97 (6H, b
r, CHCH2CH-ADM), 2.03–2.08 (5H, m, CH2CHCH2-ADM, CH2CH2CO) 
and 3.08–3.14 (2H, m, NHCH2CH2).
Synthesis of compound 8. 
Excess TFA (10 mL) was added to compound 7 (0.75 g, 2.1 mmol) 
in DCM (30 mL) at 0˚C. The solution was stirred for 2 h, concent
rated, washed with saturated NaHCO3 and brine, and dried over 
MgSO4. Compound 8 was obtained as a white solid without furthe
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r purification. Yield: 89%, 1H NMR (300 MHz, 1.2 wt% DCl in D2O): 
d 1.16–1.26 (2H, m, CH2CH2CH2), 1.40–1.56 (10H, m, CH2CH2CH2, C
CH2CH-ADM), 1.81 (6H, br, CHCH2CHADM), 1.89 (3H, br, CH2CHCH
2-ADM), 2.04–2.09 (2H, t, CH2CH2CO) and 2.80–2.85 (2H, t, NH2CH2
CH2).
 Synthesis of compound 9. 
FITC isomer 1 (0.04 mg, 0.113 mmol) was added in a solution of 
compound 8 (0.030 g, 0.11 mmol) in MeOH (5 mL), followed by sa
turated NaHCO3 (1 mL). After stirring overnight, the reaction mixt
ure was purified by reverse-phase high-performance liquid chro
matography (HPLC) with a linear gradient over 30 min from 50 to 
100% of ACN/DIW with 0.1% TFA at a flow rate of 6 mL/min. Co
mpound 9 was obtained as an orange solid. Yield: 32%, 1H NMR 
(300 MHz, MeOD): d 1.40–1.45 (2H, m,CH2CH2CH2), 1.61–1.66 (2H, 
m, CH2CH2CO), 1.69– 1.73 (8H, s, m, CCH2CH-ADM, NHCH2CH2), 2.
01 (9H, br, CHCH2CH-ADM, CH2CHCH2-ADM), 2.13–2.16 (2H, t,CH2
CH2CO), 3.65 (2H, br, NHCH2CH2), 6.55 (2H, s, 20-CH-xanthene), 
6.56–6.58 (2H, dd, 40-CH-xanthene), 7.17– 7.19 (2H, d, 50-CH-xan
thene), 7.20–7.22(1H, d,40-CHisobenzofuranone), 7.62–7.64 (1H,d,5
0-CH-isobenzofuranone), 7.82 (1H, s,70-CH-isobenzofuranone).
2.3. Measurement of pH-sensitive drug release
Release of BA from b-CD–MCM–BA pH-sensitive release of BA 
from b-CD–MCM–BA (4) was confirmed by 1H NMR. b-CD–MCM–
BA was dissolved in 1.2 wt% DCl at the concentration of 3 
mg/mL. After incubation with stirring at 37˚C for 8 h, 1H NMR 
was measured by a Bruker Avance DPX-300 (Germany) (Figure 4).
Release of CP from b-CD–MCM–CP b-CD–MCM–CP (5) was 
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dissolved in a pH 7.4 phosphate buffer (100 mM) or a pH 5.5 
acetate buffer (100mM) at a concentration of 3 mg/mL, and each 
solution was incubated with stirring at 37˚C. A YOUNGLIN HPLC 
(9000 HPLC, South Korea) equipped with a UV detector and a 
reversephase column (Agilent Eclipse XDB-C18 4.6150 mm, 5 mm) 
was used for the HPLC-based measurement. At various time 
points, each sample was collected and diluted 10 times with the 
same buffer. After filtering through a 0.2-mm polyvinylidene 
fluoride syringe filter, the sample was injected into the HPLC 
system. A mixture (3:7 v/v) of MeOH:pH 9.0 phosphate buffer 
(50mM) was used as the eluent, and the flow rate was set at 0.5 
mL/min. The release of CP was measured by UV absorbance at 
wavelengths 245 and 270 nm (Figure 5).
2.4. Complex formation between compound 5 and 9
  Fluorescence correlation spectroscopy measurement A 
home-built fluorescence confocal microscope setup was used to 
measure the autocorrelation of the fluorescent probe, FITC. A 
488-nm continuous blue laser diode (TECBL-20GC-488, World 
Star Tech, Toronto, Canada) was coupled with a single-mode op-
tical fibre (Φ=3–5 μm, P1-488-PM-FC, Thorlabs, Newton, NJ) for 
the beam clean-up and illuminated the sample through a wa-
ter-immersion objective (NA=1.20, 60Ｘ, f=3 mm, Olympus, Tokyo, 
Japan) mounted in a homemade microscope body. The fluo-
rescence signal was distinguished with the excitation light by a 
dichroic mirror (ZT488rdc, Chroma, Bellows Falls, VT) and fur-
ther cleaned by an emission filter (HQ525/50 m, Chroma). A 1:2 
multimode fibre optic coupler ((Φ=62.5 lm, FCMM625-50A-FC) was 
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used as a pinhole to reduce the background from the focal vol-
ume, and two avalanche photodiodes (SPCM-AQR-14-FC, Perkin 
Elmer, Waltham, MA) collected the fluorescence signals. The cor-
relation was measured with a correlator card(FLEX02-01D, 
Correlator.com) and further analysed by a homemade analysis 
program coded with LabVIEW 2009 (National Instruments, Austin, 
TX). The fluorescence correlation spectroscopy (FCS) setup was 
calibrated to determine the axial and lateral dimensions of the 
confocal volume by using a fluorophore, Alexa 488, whose dif-
fusion coefficient is D=4.35106×10^-6cm2/s [31]. The process fol-
lowed the procedure described in reference[32]. Calibration 
showed that the lateral 1/e2 dimension was 232 nm with the as-
pect ratio of 7.18, indicating that the measured focal volume was 
0.501 fL. For the measurement of complex formation, a solution 
of compound 9 (10 nM) in pH 9.0 phosphate buffer (50 mM) was 
prepared with different concentrations of compound 5. Bovine se-
rum albumin was added to the mixture at the final concentration 
of 0.1 mg/mL to prevent the nonspecific binding between com-
pounds 5 and 9. Each correlation curve was measured six times 
for 10 min each (once for each concentration of compound 5) to 
suppress the thermal noises and background signals. Rotating 
frame overhauser effect spectroscopy The complex between b-CD 
and compound 9 and the complex between b-CD–MCM–CP 
(compound 5) and compound 9 were prepared by mixing at a 1:1 
molar ratio at a concentration of 3mM in a D2O-based pH 9.0 
phosphate buffer (50 mM). NMR spectra recorded at 25˚C on a 
Agilent Technologies 400-MR DD2 (Santa Clara, CA) spectrometer. 
Rotating frame overhauser effect spectroscopy (ROESY) experi-
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ment was performed using the standard protocols contained in 
the spectrometer library (mixing time: 300 ms; T1 experiment).
2.5. Cytotoxicity
 Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich) assay. 
NIH-3T3 cells (mouse embryonic fibroblast cell line) were seeded 
at 5.0103 cells/well in a 96-well plate in 90 mL of Dulbecco’s 
modified eagle’s medium WelGene containing 10% foetal bovine 
serum; WelGene (Daegu, South Korea) and incubated at 37˚C for 
24 h. To determine the cytotoxicity, 10 mL of the solution of 
each sample with various concentrations was added into the 
media with subsequent incubation at 37˚C for 48 h. For the 
assay, the cells were washed with Dulbecco’s phosphate-buffered
saline (DPBS; WelGene), followed by the addition of 20 mL of 
filtered MTT solution (2 mg/mL in DPBS). After incubation at 37 ˚
C for 2 h, the medium was removed from the well, and 150 mL 
of DMSO was added to dissolve the insoluble formazan particles. 
The absorbance was measured at 570 nm using a microplate 
reader (Molecular Devices Co., Menlo Park, CA). The relative cell 
viability (%) was defined as the percentage of viable cells 




3.1. Synthesis of b-CD–MCM
  We synthesised a pH-sensitive drug carrier based on b-CD and 
MCM for efficient drug conjugation, rapid drug release at acidic 
pH and simple introduction of functional ligands. The synthetic 
scheme is shown in Figure 2(a). After the synthesis of MCM by 
the Horner–Wadsworth–Emmons reaction between trieth-
yl-2-phosphonopropionate and dimethyl-2-oxoglutarate (Figure 
2b) [29], MCM was coupled with the b-CD molecule via the for-
mation of ester bond between the carboxyl group of MCM and 
the hydroxyl group of b-CD. A b-CD molecule has seven primary 
hydroxyl groups and fourteen secondary hydroxyl groups. Among 
them, primary hydroxyl groups at the 60-C position of the glu-
cose are more reactive to electrophiles, and they preferably react 
with the carboxyl group using a carbodiimide-coupling reagent, 
DIC. b-CD–MCM was purified from the excess reagents by 
dialysis. The formation of b-CD–MCM was confirmed by 1H NMR 
and MALDI-TOF mass spectrometry (Figure 3). The numbers of 
MCM residues per a b-CD–MCM molecule was calculated to be 
six by 1H NMR. In other words, 85% of primary hydroxyl groups 
of b-CD were conjugated with MCM on average. The MALDI-TOF 
mass spectra exhibited the presence of b-CD–MCM molecules 
with various numbers of MCM residues: b-CD–(MCM)2 (1490), 
b-CD–(MCM)3 (1656), b-CD–(MCM)4 (1822), b-CD–(MCM)5 (1988), 
b-CD–(MCM)6 (2154) and b-CD–(MCM)7 (2322). Considering the 
average conjugation number was six by 1H NMR and the main 
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peak of the MALDI-TOF spectra was that
of b-CD–(MCM)4, the MALDI-TOF spectra could not represent the 
distribution of various b-CD–(MCM) molecules accurately, most 
likely due to the different ionisation degrees of the b-CD–(MCM) 
variants.
3.2.Drug conjugation with b-CD–MCM
 At first, a simple primary amine, BA, was used as a model drug 
for the optimisation of the conjugation reaction. By simple mixing 
in a weakly basic condition, BA was successfully introduced into 
b-CD–MCM. The 1H NMR spectrum shows the formation of the 
acid amide linkage between BA and b-CD–MCM (Figure 4). 
Greater than 90% of MCM moieties in b-CD–MCM were reacted 
with BA, and only a small amount of unreacted BA were 
remained. Then, CP, an amine-containing antibiotic drug, was 
conjugated with b-CD–MCM by a similar method. The formation 
of b-CD–MCM–CP was confirmed by both 1H NMR and HPLC. 
The amount of CP with a strong UV absorption was easily ana-
lysed by a UV detector. High conjugation efficiency (92.5±2.5%) 
was observed in the formation of b-CD–MCM–CP. As we applied 
six equivalents of CP to b-CD–MCM with six MCM moieties, near-
ly exhaustive conjugation was accomplished by the simple mixing. 
In addition, the drug content in b-CD–MCM–CP was calculated to 
be 28±5.5% by comparing the mass of CP and the total mass of 
b-CD–MCM–CP with some residual sodium and TEA salts.
3.3. pH-sensitive drug release
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  The pH-sensitive degradation of the MCM acid amide bond
was investigated by 1H NMR. The methylene protons (marked
with x) next to the nitrogen in the intact amide of b-CD–MCM–BA 
showed a peak at 3.18–3.23 ppm, while the peak (marked with *) 
was shifted to 2.55–2.62 ppm, equal to the methylene peak of fre
e BA, in an acidic solution (1.2 wt% DCl in D2O) (Figure 4). The c
hemical shift confirmed the degradation of the MCM acid amide a
nd the release of conjugated BA. Cumulative release of CP from 
b-CD–MCM–CP at pH 5.5 and pH 7.4 was measured by HPLC to d
etermine the degradation kinetics in more detail (Figure 5). At pH 
7.4, less than 20% of CP was released from b-CD–MCM–CP, even 
after 5 h. On the other hand, a rapid burst of CP was observed 
at pH 5.5, and more than 80% of CP was released within 0.5 h. T
he release was almost completed at approximately 95% in 1 h. A 
dramatic difference in release kinetics was observed between pH 
5.5 and pH 7.4. In addition, we confirmed the stability of CP duri
ng the conjugation and release procedure. The 1H NMR spectrum 
of the CP released from b-CD–MCM–CP at pH 5.5 was identical t
o that of the initial CP (Figure 6a). The mass spectra of the two 
CPs obtained by electrospray ionisation were also identical (350.1 
[M+H]+and 699.1 [M+M]+, Figure 6b). Based on these data, we beli
eve that CP was quite stable during the conjugation in mildly bas
ic conditions and during the release in weakly acidic conditions.
3.4. Complex formation between b-CD–MCM–CP 
and the adamantane derivative
To clarify the formation of the complex between the b-CD based
22
drug conjugate and an adamantane derivative, we used FCS, 
which analyses the variation in the diffusion coefficient of a fluo-
rophore attached to guest or host [33]. FITC was conjugated to 
the adamantane derivative [34] as a probe (FITC-hex-ADM) 
(Figure 2c). The average diffusion time of the fluorophore was 
measured with varying the concentration of the host molecule, 
b-CD–MCM–CP. As the concentration of b-CD–MCM–CP in-
creased, the average diffusion time also decreased, confirming 
the molecular weight increase and the complex formation (Figure 
7). From the graph, the binding constant between b-CD–MCM–CP 
and FITC-hex-ADM was calculated to be 1.49104 M1. 
Furthermore, 2D ROESY NMR experiment was performed to show 
the formation of the inclusion complex. Figure 8(a and b) exhibit 
the ROESY spectra of the b-CD/FITC-hex-ADM and b-CD–MCM–
CP/FITC-hex-ADM mixtures, respectively. The a, b and g protons 
of the adamantane in FITC-hex-ADM showed strong cross-peaks 
by interaction with the H3, H5 and H6 protons in the cavity of 
native b-CD, and weaker crosspeaks by interaction with the H2 
and H4 protons on the exterior of the b-CD cavity (Figure 8a). 
Similarly, the cross-peaks between the protons of the ada-
mantane derivatives and b-CD–MCM–CP were also observed 
(Figure 8b). The spectra represent the spatial proximity at the 5 
Å maximal limit among the protons of b-CD derivatives and the 
adamantane moiety. Both data strongly indicate complex for-
mation between b-CD–MCM–CP and FITC-hex-ADM.
3.5. Cytotoxicity
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The short-term biocompatibility of the b-CD–MCM drug carrier 
was preliminarily checked by MTT assay on NIH3T3 cells (Figure 
9). Branched polyethylenimine 25 kDa, a wellknown polymeric 
drug delivery carrier with high cytotoxicity, was used as a 
positive control. Up to 100 lM, b-CD, b-CD–MCM and b-CD–MCM
–CP exhibited almost no cytotoxicity until 48 h.
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4. Discussion
  In this study, we intended to develop a pH-sensitive drug car-
rier that could sense the small pH drop from 7.4 to 5.5 and rap-
idly release the conjugated drug molecules. A backbone with 
many conjugating residues was preferred for high drug contents. 
In addition, various functions can be introduced by a simple 
method for a multi-role drug delivery carrier. We selected b-CD 
as the backbone of the carrier due to high biocompatibility [20], 
modifiability of many hydroxyl groups [24] and strong non-co-
valent complex formation with adamantane [27]. As a pH-sensi-
tive linker, we selected a maleic acid amide derivative because it 
can be easily synthesised by the simple mixing between the cor-
responding anhydride and amine and it shows pH-dependent 
degradability. A maleic acid amide derivative has a cis-b-carbox-
ylate group that can internally attack the carbonyl group of the 
amide via five-membered ring formation, and it shows much 
higher vulnerability than a simple amide [20,35]. The pHsensitivity 
is also dependent upon the alkyl substituent on the cis-double 
bond. Bulkier substituents can accelerate the internal attack of 
the b-carboxylate group to increase the degradability at weakly 
acidic pH [36]. Among various maleic acid amide derivatives, we 
selected the MCM acid amide because it showed rapid degrad-
ability at pH 5.5 owing to the methyl and carboxyethyl sub-
stituents [22,37,38].We successfully synthesised b-CD–MCM via a 
one-step reaction by the carbodiimide coupling method using DIC 
(Figure 2) under catalysts of DMAP and PTSA. Although coupling 
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reactions of MCM using thionyl chloride (SOCl2) or oxalyl chloride 
were reported previously [39], they showed significant side re-
actions in the coupling between b-CD and MCM, so we selected 
the DIC coupling method to achieve a high yield of the product. 
The addition of both DMAP and PTSA could facilitate the ester 
formation without the formation of side products including 
N-acylurea in polar solvents [40]. We could control the numbers 
of MCM residues that coupled to b-CD by adjusting the amount 
of reactants, and consequently obtain a ‘‘medusa-like’’ b-CD–
MCM with six MCM residues on average, which was confirmed by 
1H NMR and mass spectroscopy (Figure 3). Because the face of 
the secondary hydroxyl groups in b-CD readily interacts with an 
adamantane guest molecule [41], the medusa-like structure by 
the modification of primary hydroxyl group would be preferred 
for the future inclusion of a functional moiety. We expected a 
high efficiency in the drug conjugation with b-CD–MCM because 
the anhydride group of MCM is very reactive with nucleophiles 
such as primary amines in alkaline conditions, even if the nucle-
ophilic attack is interfered with by steric hindrance. In both cas-
es of b-CD–MCM–BA and b-CD–MCM–CP, we similarly observed 
high drug efficiency, with the values of 90% and 92.5% for BA 
and CP, respectively. By the covalent conjugation with b-CD–
MCM, the drugs can avoid premature release from the drug de-
livery carrier in the diluted concentrations in physiological fluids. 
We investigated the drug-release kinetics of b-CD–MCM–CP at pH 
5.5 and pH 7.4. Remarkably, CP was dramatically released from 
b-CD–MCM at pH 5.5 up to 80% within 0.5 h and 95% within 1 h, 
while it was barely released at pH 7.4 (Figure 5). The chemical 
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stability of CP during the conjugation and release was also 
secured. On the basis of the delicate sensing of the small pH dif-
ference and the outstanding release kinetics at the weakly acidic 
pH, we believe that b-CD–MCM can be used as a drug carrier 
for targeting tumours, inflammatory tissues or abscesses as well 
as for early endosomal escape in intracellular drug delivery. 
b-CD–MCM–CP enables the delivery of antibiotics into pneumonia 
or other inflamed tissues specifically, to avoid side effects and 
overdoses. As mentioned above, b-CD is a cyclic oligosaccharide 
composed of seven-membered a-D-glucopyranoside units linked 1 
to 4, and it contains a less hydrophilic interior space and a more 
hydrophilic outer surface. This allows b-CD to form inclusion 
complexes with various molecules through host-guest 
interactions. Adamantane, a cycloalkane consisting of four con-
nected cyclohexane rings, is the most representative guest mole-
cule for b-CD. Therefore, we can introduce a functional moiety 
such as a targeting ligand or a cell penetrating peptide into b-CD
–MCM by the tethering of an adamantane residue in the func-
tional moiety and the simple mixing with b-CD–MCM. For the 
confirmation of this concept, we synthesised a FITC-labelled ada-
mantane derivative to trace the inclusion complex by FCS. The 
diffusion coefficient of the fluorophore was decreased sig-
nificantly due to the complex formation. The binding constant 
was calculated from the ‘‘S’’-type curve between the diffusion
time and the concentration of b-CD–MCM (Figure 7). The binding 
constant K was 1.49104 M1, meaning the interaction between 
b-CD–MCM–CP and the adamantane derivative was similar to the 
general b-CD/adamantane host–guest interaction because the 
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general association constant K is 1–10104 M1 [42]. Based on the 
binding constant, the inclusion percentage could also be calcu-
lated and be shown in Figure 7. The host–guest inclusion be-
tween b-CD–MCM–CP and adamantane derivative was further 
confirmed by ROESY spectra (Figure 8). Strong cross-peaks in 
b-CD–MCM–CP/FITC-hex-ADM were comparable with those of 
b-CD/FITChex- ADM. The medusa-like conjugation of six MCM 
molecules in the face of primary hydroxyl groups did not affect 
the inclusion significantly. Based on these results, any functional 
moieties could be introduced into b-CD–MCM after the drug con-
jugation by the formation of the inclusion complex. Of course, 
other drug carriers such as polymers or nanoparticles with ada-
mantane moieties can be easily modified with b-CD–MCM through 
the host–guest interaction for pH-sensitive conjugation of drugs 
or other functionalities. Finally, we verified that b-CD–MCM and 
its drug conjugate showed almost no sign of acute cytotoxicity up 
to 100 lM in a eukaryotic cell line by MTT assay (Figure 9), al-
though the long-term toxicity and bioadaptability should be ana-
lysed by various methods in the future. As a novel drug-con-
jugating system, b-CD–MCM has great advantages in easy con-
jugation of drugs and multifunctionalities as well as rapid release 
of drugs responding to small pH drop. CP, an antibiotic model 
drug in this research, can be specifically delivered into bac-
teria-infected sites by a b-CD–MCM-based drug carrier. b-CD–
MCM, with a molar mass of several thousands, can be used as a 
pH-sensitive drug carrier by itself for a site-specific delivery of 
drugs into weakly acidic targets such as tumours, abscesses or 
inflammatory tissues. For longer circulation or enhanced perme-
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ability and retention effect, b-CD–MCM can be introduced into 
other drug delivery carriers with several hundred nanometres by 
non-covalent interactions. The future animal study will be fol-
lowed for the proof of the specificity and efficacy of b-CD–
MCM-based drug delivery systems. 
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5. Conclusion
We successfully developed a novel drug delivery carrier,b-CD–
MCM, which has a rapid release profile in response to a small 
pH drop. b-CD–MCM possesses several ready-to-use anhydride 
residues for simple and almost exhaustive conjugation with 
amine-containing drugs. b-CD–MCM–CP, one of the drug 
conjugates, exhibited a remarkable capability to discriminate 
between pH 7.4 and 5.5 to release the conjugate antibiotic. 
Moreover, the internal cavity of b-CD–MCM–CP is easily 
accessible for complexation with other functional groups with an 
adamantane residue. Based on these attractive characteristics, 
b-CD–MCM has great potential as a multifunctional drug delivery 
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Figure 1. General scheme of pH-sensitive drug delivery by a 
medusa-like β-CD–MCM.
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Figure 2. Synthetic schemes of β-CD–MCM and its drug 
conjugate. (a) Synthesis of β-CD–MCM–BA and β-CD–MCM–CP, (b) 
Synthesis of 1-methyl-2-(20-carboxyethyl) maleic anhydride 
(MCM) and (c) synthesis of FITC-hex-ADM.
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Figure 3. Confirmation of synthesis of β-CD–MCM. (a) 1H NMR 
(NMR solvent: D2O) and (b) MALDI-TOF spectra of β-CD–MCM.
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Figure 4. Release of BA from β-CD–MCM–BA at acidic pH 
measured by 1H NMR (NMR solvent: D2O).
40
Fig. 5. pH-responsive release of CP from β-CD–MCM–CP at pH 
5.5 (acetate buffer, 100mM; ○) and pH 7.4 (phosphate buffer, 100 
mM; □) measured by HPLC. The error bar represents the stand-
ard deviation
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Figure 6. Identification of the released CP from β-CD–MCM–CP. 
(a) 1H NMR (NMR solvent: D2O) and (b) ESI mass spectra of the
released CP.
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Figure 7. Variation of the average diffusion time measured by FCS 
to confirm the complex formation between β-CD–MCM–CP and 
FITC-hex-ADM.
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Figure 8. Expansion of NMR 2D ROESY (NMR solvent: D2O) 
spectra of the inclusion complex between (a) β-CD and 
FITC-hex-ADM and (b) β-CD–MCM–CP and FITC-hex-ADM.
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Figure 9. Cytotoxicity in NIH3T3 cells of β-CD (□), β-CD–MCM 
(◇), β-CD–MCM–CP (○), CP (△) and PEI (■). Each error bar 
represents the standard deviation (n=3).
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국문 초록
우리는 β-사 클 스트린과 말 산 수 에 한 pH에 민감한 약
달 운 체  개 했다. β-사 클 스트린  1차 OH작용  말 산 
수  잔 가 공  결합  루어  사 형태  같  β-cd-mcm
 형 했다. MCM 잔 는 프라  약 과 높  효  (490%) 결합  
형 했다. 욱  주목할 만한 것  βcd-mcm-cp는 pH가 7.4에  5.5  떨
어지는 작  변화에 도 80% 상  약  30 만에 떨어지는 것  보여
주었다는 것 다. 아다만탄 생  β-cd-mcm-cp  간단  어주는 것만
도 β-사 클 스트린  안  공간  삽 는 것  알 수 는  
러한 사실  통하여 다양한 작용 들  도 할 수 다. 러한 다양한 
장 들  통해 βcd-mcm  약산  직 나 장 ,  들  암 포나 
감염 직, 양, 엔도  목  약  달 할 수 다. 그리고 아다만
탄 끝에 특  질  가진 질,  들  리간드나 포 과  질  
쉽게 붙 는 것  가능해  욱  효과  약 달체가  수  것
 상 다.
주요어: 프라 , 약  달, 말 산 수 , 아다만탄, 사 클 스트
린
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